Statement on the appointment Dr Renata Crome, Non-Executive Director.

Solvonis announces the appointment of Dr Renata Crome as Non-Executive Director

Renata is a pharmaceutical industry veteran with 40 years of experience in scientific and clinical development, regulatory approval, and commercialisation of breakthrough medicines. A recognised leader in CNS, oncology, and infectious diseases, she has guided over 100 novel therapies from research to first-in-human trials.

After a 30-year tenure at Roche, Dr. Crome became Deputy Head of Early Development & Global Head of Development Operations, managing a team of 250+ professionals and 100+ early-stage programs. She played a key role in the commercialisation of blockbuster drugs like Avastin® and Tamiflu®, driving US$7 billion and US$3 billion in peak sales, respectively.

Dr. Crome currently consults for Novo Nordisk and led the UK Government’s UKRI-sponsored COVID-19 treatments program. She also served as a Non-Executive Director at Camcon Robotics and is involved with the PTEN Research Foundation, Success Charity, and Isabel Hospice.